Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 10/20 | 0.58 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.52 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8080186 | 1.00 | LTA4H (0.58) | LTA4HFFAR1MAPTLMNAALDH1A1 | |
| SCHEMBL10203407 | 1.00 | LTA4H (0.58) | LTA4HFFAR1MAPTLMNAALDH1A1 | |
| SCHEMBL12549253 | 0.94 | LTA4H (0.59) | LTA4HMAPTLMNAALDH1A1HPGD | |
| SCHEMBL14534754 | 0.88 | LTA4H (0.56) | LTA4HFFAR1MAPTLMNAALDH1A1 | |
| SCHEMBL14534753 | 0.88 | LTA4H (0.56) | LTA4HFFAR1MAPTLMNAALDH1A1 | |
| SCHEMBL14570538 | 0.88 | MEN1 (0.59) | LTA4HFFAR1MAPTSMN1; SMN2CYSLTR2 | |
| SCHEMBL15104736 | 0.86 | NR5A1 (0.60) | LTA4HFFAR1MAPTCYSLTR2CYSLTR1 | |
| SCHEMBL19474670 | 0.86 | LTA4H (0.53) | LTA4HFFAR1MAPTSMN1; SMN2CYSLTR2 | |
| SCHEMBL7747836 | 0.86 | NR5A1 (0.60) | LTA4HFFAR1MAPTCYSLTR2CYSLTR1 | |
| SCHEMBL13104320 | 0.86 | LMNA (0.53) | LTA4HMAPTLMNAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102599-B2 | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-11 | — | — | US | disclosed |
| US-20130184279-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-18 | — | — | US | disclosed |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-20 | — | — | US | disclosed |
| US-8304403-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-06 | — | — | US | disclosed |
| EP-1951673-B1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-09-05 | — | — | EP | disclosed |
| EP-1951690-B1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-1954668-B9 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-1954668-B1 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-7790770-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-7674828-B2 | Urea antagonists of P2Y1receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-09 | — | — | US | disclosed |
| US-7652023-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-26 | — | — | US | disclosed |
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007062314-A2 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY2 | LTA4H 684/4885FFAR1 112/4885MAPT 3475/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | LTA4H 1274/4885FFAR1 518/4885MAPT 4114/4885 |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | LTA4H 1274/4885FFAR1 518/4885MAPT 4114/4885 |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | LTA4H 1274/4885FFAR1 518/4885MAPT 4114/4885 |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | LTA4H 1274/4885FFAR1 518/4885MAPT 4114/4885 |
| US-20130184279-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | CETP, APOB, CES1 | LTA4H 1769/4885FFAR1 290/4885MAPT 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.